Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:18 AM
October 2025
In this session, Sarah Dawkins, NP, breaks down the overlap between MASLD and MetALD using a real case (FIB-4 = 2.01, FibroScan 11.4 kPa [F3], CAP 310). Presented via the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, she reviews how to stage disease with non-invasive tests (FIB-4, FibroScan/VCTE), why alcohol biomarkers (PEth) matter, and when to initiate HCC surveillance. Practical takeaways include counseling on a Mediterranean diet, exercise/weight loss targets, alcohol abstinence, and assessing candidacy for resmetirom in metabolic-predominant cases to slow fibrosis and improve outcomes.
Related Webcast
Webcast: MASLD Basics With Suzanne Robertazzi
July 2025
Join Suzanne, a nurse practitioner from the Washington DC VA Medical Center, as she kicks off a comprehensive lecture series on steatotic liver disease, focusing on the evolving understanding of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). In this foundational session, Suzanne walks through the new nomenclature replacing NAFLD and NASH, and outlines the clinical criteria used to identify and stratify patients along the MASLD–MASH spectrum. Learn how metabolic risk factors such as obesity, prediabetes, hypertension, and dyslipidemia contribute to disease progression, and explore the use of non-invasive diagnostic tools like Fib-4, FibroScan, and ELF scores to assess fibrosis. The session also discusses indications for liver biopsy, the implications of overlapping etiologies (like alcohol-associated liver disease), and strategies for identifying patients at high risk for cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. This lecture equips clinicians, particularly those in primary care and hepatology, with a practical framework to evaluate steatosis, interpret metabolic profiles, and determine when to refer patients for specialty care. Whether you're new to liver disease or looking for updates on MASLD and MASH terminology, this session is an essential starting point.
Watch Now
Webcast: MASLD Basics With Tessa Janovsky
August 2025
Join Tessa Janovsky, PA-C, from Arizona Liver Health, for this foundational session in the GHAPP MASLD Community Network, proudly sponsored by Madrigal Pharmaceuticals. This episode offers a comprehensive overview of the updated nomenclature and clinical approach to steatotic liver disease, covering the transition from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Tessa breaks down the rationale behind this global reclassification and explains how it improves diagnostic clarity while reducing stigma. You’ll learn how to identify MASLD using cardiometabolic risk factors, apply non-invasive risk stratification tools like FIB-4, FibroScan, and ELF, and determine when to refer patients for hepatology care. She also discusses the natural history of MASLD progression, the risk of cirrhosis and HCC, and the clinical importance of early detection and treatment. Real-world case studies guide providers through assessing common patient presentations, ruling out alternative etiologies, and considering pharmacologic therapy like resmetirom when appropriate. This is an essential watch for APPs, PCPs, and GI providers working to better understand and manage MASLD and MASH in clinical practice.
Watch Now
Webcast: MASLD vs MetALD With Milly Ng
October 2025
Milly Ng explores the intersection of metabolic dysfunction–associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)—known as MetALD. Through a real-world patient case, she explains how metabolic risk factors like obesity, hypertension, and dyslipidemia interact with alcohol use to accelerate liver damage, fibrosis, and HCC risk. Learn how to identify and manage MetALD using FibroScan, PEth testing, and evidence-based strategies including lifestyle modification, alcohol cessation, and emerging therapies like resmetirom.
Watch Now
Webcast: Lifestyle Management With Alison Moe
August 2025
Join Alison Moe, PA-C, from Atlanta Gastroenterology Associates, as she walks through a real-world clinical case highlighting the challenges and strategies in managing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In this engaging and educational session, Alison shares the case of a 65-year-old Hispanic male with obesity, type 2 diabetes, and fatty liver disease—diving deep into non-invasive diagnostic tools, including FIB-4 scoring and FibroScan, and how these help guide risk stratification for liver fibrosis. The discussion emphasizes the crucial role of dietary counseling, culturally sensitive lifestyle modifications, and exercise guidance to slow or even reverse disease progression. Learn how to set achievable goals for patients and explore effective methods for improving glycemic control, BMI, and overall liver health. Alison also touches on evidence-based interventions such as the Mediterranean diet, resistance training, and intermittent fasting, supported by AASLD and European liver guidelines. Whether you're a clinician treating MASLD or simply interested in the evolving approach to fatty liver disease, this case study offers practical takeaways and guidance to optimize patient outcomes.
Watch Now
Webcast: MASLD Pharmacotherapy With Marcella Pomeranz
October 2025
In this educational session, Marcella Pomeranz, DNP, explores the evolving pharmacotherapy options for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction–Associated Steatohepatitis (MASH). Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk reviews both established and emerging therapies—from GLP-1 receptor agonists and pioglitazone to vitamin E and the recently approved resmetirom (Rezdiffra). Marcella discusses practical considerations for treatment selection, dosing adjustments, and medication safety, along with strategies to combine pharmacologic therapy with diet, exercise, and lifestyle modification to slow fibrosis progression and improve liver outcomes.
Watch Now
Webcast: MASLD Pharmacotherapy With Suzanne Robertazzi
September 2025
Join Suzanne Robertazzi, DNP for a clinician-focused update on MASH and MASLD pharmacotherapy—what to treat, when to treat, and how to monitor. This talk reviews the shift to MASLD/MASH terminology, why management must target the entire metabolic syndrome (obesity, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risk), and the practical role of weight loss (diet, physical activity, anti-obesity medications, bariatric surgery). Suzanne explains where GLP-1 receptor agonists fit (mechanism, expected benefits, GI/aspiration precautions and holding doses before procedures), clarifies that statins are safe in fatty liver, and summarizes legacy data and limitations for vitamin E and pioglitazone. She then covers the first FDA-approved therapy for non-cirrhotic MASH with F2–F3 fibrosis, resmetirom—including THR-β–selective mechanism, tolerability, key drug–drug interactions (and statin dose limits), and real-world considerations such as insurance requirements, staging with FIB-4 and FibroScan®/NITs, restaging cadence, and treatment duration. If you’re a GI/hepatology clinician or APP, this session delivers evidence-based, step-by-step guidance to streamline risk reduction, staging, and therapy for patients with MASLD/MASH.
Watch Now
Webcast: MASLD Basics With Chantil Jeffreys
September 2025
In this MASLD/MASH Community Network “Basics” session, Chantil Jeffreys, FNP clarifies the new MASLD/MASH nomenclature, how to recognize metabolic criteria (obesity, dyslipidemia, hypertension, impaired glucose/A1C, low HDL), and when to rule out other causes (alcohol overlap, DILI, cryptogenic disease). She walks through a practical primary-care workflow: start with FIB-4, then risk-stratify with FibroScan or ELF, identify patients who need hepatology referral, and decide when liver biopsy is appropriate (discordant/indeterminate NITs, suspected concomitant disease, select older patients). The talk covers global prevalence, natural history and progression (F0→F4/cirrhosis→HCC), and why aggressive cardiometabolic risk reduction and appropriate surveillance matter. You’ll leave with a clear algorithm to stage disease, monitor over time, and communicate the MASLD/MASH shift to colleagues and patients.
Watch Now
Webcast: MASLD Pharmacotherapy With Gabriella McCarty
August 2025
In this presentation, Gabriella McCarty, NP-C at Oshi Health, explores the evolving management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MASH with a focus on pharmacotherapy. Drawing from her 26 years in gastroenterology, IBD, and hepatology, she explains how fatty liver disease is often detected incidentally and highlights the importance of early diagnosis and patient education. Gabriella reviews the three-pillar approach to treatment—lifestyle and weight loss strategies, cardiovascular risk reduction, and emerging liver-directed therapies. She discusses the role of GLP-1 receptor agonists, Vitamin E, Pioglitazone, and the first FDA-approved therapy, Resmetirom, detailing their mechanisms, benefits, and safety considerations. With insights from the MAESTRO-NASH trial and real-world experience using non-invasive tests like FibroScan, CAP scores, and ELF testing, this session provides practical guidance for clinicians managing MASLD/MASH and preventing disease progression to cirrhosis or hepatocellular carcinoma.
Watch Now
Webcast: MASLD Basics With Summer Collier
July 2025
Join Summer Collier, NP from UC San Diego Health, for an essential overview of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) in this GHAPP MASLD Community Network session. Designed for clinicians and healthcare professionals, this case-based talk covers the evolving nomenclature shift from NAFLD/NASH to MASLD/MASH, including key definitions, diagnostic criteria, and practical tools for identifying and managing patients with steatotic liver disease. Summer walks through foundational concepts like the role of hepatic steatosis, cardio-metabolic risk factors, and the importance of excluding significant alcohol use to establish a MASLD diagnosis. She also provides clinical insights into non-invasive fibrosis staging using FIB-4, FibroScan, elastography, and blood-based tests, as well as how to differentiate patients who may require hepatology referral or biopsy. Emphasizing the importance of early detection and risk stratification in primary care, this session highlights how fibrosis stage impacts prognosis, treatment planning, and long-term liver-related outcomes. For more educational sessions and MASLD tools — visit the GHAPP MASLD Community Network.
Watch Now
Webcast: MASLD Pharmacotherapy With Jeremy Davis
September 2025
In this clinician-focused talk, Jeremy Davis, NP, delivers a clear, practical guide to MASLD/MASH pharmacotherapy—from foundational lifestyle and weight-loss strategies to medications that move the needle. He reviews the role of GLP-1 receptor agonists (and emerging dual agonists) for weight reduction and glycemic control, peri-procedure considerations (delayed gastric emptying/aspiration risk), and where legacy options like vitamin E (select non-diabetic, non-cirrhotic patients) and pioglitazone fit, including benefits and safety trade-offs. The session spotlights resmetirom—the first FDA-approved, liver-directed THR-β agonist for non-cirrhotic MASH with F2–F3 fibrosis—covering its mechanism, key MAESTRO-NASH data, common AEs (nausea/diarrhea), and practical drug–drug interaction/statin-dosing considerations. You’ll also learn how to structure follow-up with non-invasive testing (FibroScan kPa/CAP, ELF, labs), set measurable lifestyle goals, coordinate cardiometabolic risk reduction (T2D, hypertension, dyslipidemia), and navigate coverage and duration questions—so you can confidently tailor therapy and improve outcomes across the MASLD/MASH spectrum.
Watch Now